TW200501957A - Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin Ⅱ antagonist for stroke prevention - Google Patents

Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin Ⅱ antagonist for stroke prevention

Info

Publication number
TW200501957A
TW200501957A TW093103344A TW93103344A TW200501957A TW 200501957 A TW200501957 A TW 200501957A TW 093103344 A TW093103344 A TW 093103344A TW 93103344 A TW93103344 A TW 93103344A TW 200501957 A TW200501957 A TW 200501957A
Authority
TW
Taiwan
Prior art keywords
dipyridamole
angiotensin
antagonist
combination
stroke
Prior art date
Application number
TW093103344A
Other languages
English (en)
Chinese (zh)
Inventor
James C Gilbert
Lutz Hilbrich
Axel Riedel
David Michael Humphreys
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32870338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200501957(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200501957A publication Critical patent/TW200501957A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093103344A 2003-02-13 2004-02-12 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin Ⅱ antagonist for stroke prevention TW200501957A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10306179A DE10306179A1 (de) 2003-02-13 2003-02-13 Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
EP03018212 2003-08-08

Publications (1)

Publication Number Publication Date
TW200501957A true TW200501957A (en) 2005-01-16

Family

ID=32870338

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093103344A TW200501957A (en) 2003-02-13 2004-02-12 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin Ⅱ antagonist for stroke prevention

Country Status (29)

Country Link
US (5) US20040214802A1 (enExample)
EP (2) EP1733729A1 (enExample)
JP (1) JP2006517557A (enExample)
KR (1) KR20050100676A (enExample)
CN (1) CN1750830A (enExample)
AR (1) AR043173A1 (enExample)
AT (1) ATE395921T1 (enExample)
AU (1) AU2004212305A1 (enExample)
BR (1) BRPI0407457A (enExample)
CA (1) CA2515941A1 (enExample)
DE (2) DE10306179A1 (enExample)
DK (1) DK1603573T3 (enExample)
EA (1) EA200501231A1 (enExample)
EC (1) ECSP055963A (enExample)
ES (1) ES2308147T3 (enExample)
HR (1) HRP20050713A2 (enExample)
MX (1) MXPA05008572A (enExample)
NO (1) NO20054216L (enExample)
NZ (1) NZ542302A (enExample)
PE (1) PE20050191A1 (enExample)
PL (1) PL378204A1 (enExample)
PT (1) PT1603573E (enExample)
RS (1) RS20050618A (enExample)
SI (1) SI1603573T1 (enExample)
TW (1) TW200501957A (enExample)
UA (1) UA83481C2 (enExample)
UY (1) UY28182A1 (enExample)
WO (1) WO2004071385A2 (enExample)
ZA (1) ZA200505956B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
CA2437709A1 (en) * 2003-08-08 2005-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events
JP2005060359A (ja) * 2003-08-13 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co Kg 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンii拮抗薬の使用
WO2009080301A1 (en) * 2007-12-21 2009-07-02 Boehringer Ingelheim International Gmbh Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2010097501A2 (en) * 2009-02-26 2010-09-02 Orion Corporation A combination treatment
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
WO2016119701A1 (en) 2015-01-28 2016-08-04 Realinn Life Science Limited COMPOUNDS FOR ENHANCING PPARγ EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031458A (en) * 1958-02-05 1962-04-24 Ciba Pharm Prod Inc Isoindolines
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3317279A (en) * 1963-03-15 1967-05-02 Pennsalt Chemicals Corp Polymorph of calcium disilicide and its method of preparation
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
US4318477A (en) * 1980-09-22 1982-03-09 Kerpe Stase Z Pharmaceutical package
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3627423A1 (de) 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
EP1013273A1 (en) 1998-12-23 2000-06-28 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
JP2002138054A (ja) * 2000-08-25 2002-05-14 Takeda Chem Ind Ltd フィブリノーゲン低下剤
JP2002293742A (ja) * 2001-01-29 2002-10-09 Takeda Chem Ind Ltd 鎮痛・抗炎症剤
JP2003212758A (ja) * 2001-03-16 2003-07-30 Takeda Chem Ind Ltd 徐放性製剤の製造法
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe

Also Published As

Publication number Publication date
ATE395921T1 (de) 2008-06-15
SI1603573T1 (sl) 2008-10-31
HRP20050713A2 (en) 2006-09-30
ECSP055963A (es) 2006-01-16
KR20050100676A (ko) 2005-10-19
EP1603573B8 (en) 2009-04-01
US20070004687A1 (en) 2007-01-04
WO2004071385A2 (en) 2004-08-26
EP1603573A2 (en) 2005-12-14
RS20050618A (sr) 2007-09-21
EP1733729A1 (en) 2006-12-20
US20040214802A1 (en) 2004-10-28
CA2515941A1 (en) 2004-08-26
BRPI0407457A (pt) 2006-01-31
DE10306179A1 (de) 2004-08-26
ZA200505956B (en) 2006-03-29
ES2308147T3 (es) 2008-12-01
UY28182A1 (es) 2004-09-30
US20080188497A1 (en) 2008-08-07
DK1603573T3 (da) 2008-09-15
EA200501231A1 (ru) 2006-02-24
NO20054216D0 (no) 2005-09-12
UA83481C2 (uk) 2008-07-25
AU2004212305A1 (en) 2004-08-26
WO2004071385A3 (en) 2005-01-06
DE602004013937D1 (de) 2008-07-03
CN1750830A (zh) 2006-03-22
US20060241089A1 (en) 2006-10-26
PT1603573E (pt) 2008-06-26
NO20054216L (no) 2005-09-12
JP2006517557A (ja) 2006-07-27
US20080113949A1 (en) 2008-05-15
AR043173A1 (es) 2005-07-20
MXPA05008572A (es) 2005-11-04
NZ542302A (en) 2008-12-24
PE20050191A1 (es) 2005-04-12
EP1603573B1 (en) 2008-05-21
PL378204A1 (pl) 2006-03-20

Similar Documents

Publication Publication Date Title
MXPA04006275A (es) Composiciones farmaceuticas que comprenden un inhibidor de fosfodiesterasa multifuncional y un inhibidor de captacion de adenosina.
IL178128A0 (en) Salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid and pharmaceutical compositions containing the same
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2008123582A1 (ja) テトラヒドロイソキノリン化合物
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
MXPA05008572A (es) Uso de dipiridamol en combinacion con acido acetilsalicilico y un antagonista de angiotensina ii para la prevencion de accidente cerebrovascular.
EP2332526A3 (en) Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
TN2009000119A1 (en) Combination drug
EP1637167A3 (en) New injectable formulations containing progesterone
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
DK1220676T3 (da) Forebyggelse af colorektal cancer
DE602006013792D1 (de) Pharmazeutische zusammensetzungen mit nep-inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika
WO2003061572A8 (en) Anti-inflammatory formulations
WO2007046842A3 (en) Composition for inhibition of cathepsin k
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
BRPI0416906A (pt) proteinúria tubular como um indicador para risco cardiovascular elevado
WO2005035746A3 (en) Medical use of tbk-1 or of inhibitors thereof
MXPA04006269A (es) Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.
GB0128071D0 (en) Medicament
WO2005105062A3 (de) Kombinationspräparate enthaltend 2-methylthiazolidin-2,4-dicarbonsäure
UA90162C2 (ru) Фармацевтическая композиция на основе ингибитора обратной транскриптазы и мелдония
DK1389122T3 (da) Forebyggelse af epitelcancer
BR0303110A (pt) Uso de dipiridamol, ácido acetilsalicìlico e um antagonista de angiotensina ii para tratamento e prevenção de eventos vasculares